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authorizations for the treatment of relapsing-remitting multiple
sclerosis (RRMS). Given their appraisal by the National Institute for
Health and Care Excellence, the objective was to systematically
identify and critically evaluate the structures and assumptions used
in health economic models of disease-modifying therapies for RRMS
in the United Kingdom. Methods: Embase, MEDLINE, The Cochrane
Library, and the National Institute for Health and Care Excellence Web
site were searched systematically on March 3, 2014, to identify articles
relating to health economic models in RRMS with a UK perspective.
Data sources, techniques, and assumptions of the included models
were extracted, compared, and critically evaluated. Results: Of 386
results, 26 full texts were evaluated, leading to the inclusion of 18
articles (relating to 12 models). Early models varied considerably in
method and structure, but convergence over time toward a Markov
model with states based on disability score, a 1-year cycle length, and
a lifetime time horizon was apparent. Recent models also allowed foree front matter Copyright & 2015, International S
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Considerable variety remains, with increasing numbers of compara-
tors, the need for treatment sequencing, and different assumptions
around efﬁcacy waning and treatment withdrawal. Conclusions:
Despite convergence over time to a similar Markov structure, there
are still signiﬁcant discrepancies between health economic models of
RRMS in the United Kingdom. Differing methods, assumptions, and
data sources render the comparison of model implementation and
results problematic. The commonly used Markov structure leads to
problems such as incapability to deal with heterogeneous populations
and multiplying complexity with the addition of treatment sequences;
these would best be solved by using alternative models such as
discrete event simulations.
Keywords: cost-effectiveness, health economics, multiple sclerosis,
systematic review.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Multiple sclerosis (MS) is a chronic immune-mediated disease
characterized by inﬂammation in the central nervous system [1].
It affects more than 100,000 people in the United Kingdom and is
the most common cause of disability in working-age adults [2].
For most of the patients, symptoms such as movement problems
and sensory disturbances initially follow a relapsing-remitting
pattern (relapsing-remitting multiple sclerosis [RRMS]), but over
time disability progresses until the disease enters the secondary-
progressive phase (secondary-progressive multiple sclerosis
[SPMS]) [3]. MS has a signiﬁcant impact on patients’ health-
related quality of life [4]. The economic burden of the disease is
also substantial and increases with disease severity and during
relapses [5]. A number of immunomodulatory drugs are nowavailable for the treatment of RRMS. Because these reduce the
number of relapses, and may reduce disability progression and/or
slow down the observed changes on magnetic resonance imaging
scans, these are collectively referred to as disease-modifying
therapies (DMTs) [6].
A number of DMTs have marketing authorizations in the
European Union for the treatment of RRMS, and the National
Institute for Health and Care Excellence (NICE) in the United
Kingdom has undertaken health technology appraisals of beta
interferons and glatiramer acetate (2002), natalizumab (2007),
ﬁngolimod (2012), teriﬂunomide (2014), alemtuzumab (2014), and
dimethyl fumarate (2014). NICE prefers that technology appraisals
be conducted from the cost perspective of the National Health
Service (NHS) and Personal Social Services (PSS), so the economic
beneﬁts of DMTs should be balanced against their direct costs. Inociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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quality-of-life improvements over a patient’s lifetime need to be
taken into account by decision makers when deciding whether
each DMT is to be reimbursed. The NICE appraisal process for beta
interferons and glatiramer acetate in MS ran from August 1999 to
February 2002, leading to controversy because NICE found all the
economic models presented unsatisfactory. Appeals against the
initial draft guidance were upheld, prompting NICE to commission
a satisfactory model to inform its reconsideration of the initial
proposed guidance. In the published ﬁnal guidance, NICE was
unable to recommend beta interferons and glatiramer acetate but
these were subsequently made available on the NHS under a
risk-sharing scheme. Natalizumab, ﬁngolimod, teriﬂunomide,
alemtuzumab, and dimethyl fumarate all received positive recom-
mendations in the RRMS population, or subgroup(s) thereof.
Considerable complexity in modeling is required to adequately
capture the natural history of MS, and, as such, models presented to
decision makers to this point have been highly variable in their
characteristics. Four recent review articles have considered aspects
of economic modeling in RRMS. Guo et al. [7] reviewed the
methodological challenges of modeling the cost-effectiveness of
DMTs in MS, focusing on long-term (Z10 years) cost-effectiveness
analyses with homogeneous contexts of analysis, published over
the previous decade. They included 12 studies and identiﬁed several
major issues associated with the included studies, including great
variations in model designs and assumptions; repetitive use of an
old data source for the natural history of disease progression;
infrequent use of comparative efﬁcacy data from head-to-head
clinical trials or network meta-analyses; and no consideration of
switching to other DMTs after initial treatment discontinuation.
Thompson et al. [8] discussed the methodological challenges in
modeling the cost-effectiveness of treatments for MS. Their review
included 36 published models and analyses and found that the
greatest source of uncertainty was the absence of head-to-head
randomized controlled trials (RCTs). Major drivers of results
included the time horizon modeled and DMT acquisition costs.
Hawton et al. [9] conducted a review to identify all published
economic evaluations of MS treatments to suggest practical recom-
mendations for future research to aid decision making. They
included 37 articles; estimates for utilities, costs, and impact of
treatment on the course of MS varied considerably between studies.
They identiﬁed issues concerning the wide variation in costs and
outcomes from different sources, from potentially unrepresentative
samples, and the modeling of disease progression from natural
history data from over 30 years ago. Yamamoto and Campbell [10]
evaluated the quality of recent cost-effectiveness studies. They
included 22 articles in their review and found that most studies
(68%) achieved the highest quality category. To continue to improve
the cost-effectiveness evidence for DMTs, several recommendations
were made, including using lifetime horizons; the development of
modeling and input standards for comparability; head-to-head RCTs
between DMTs and long-term prospective studies; and comprehen-
sive cost-effectiveness studies that compare all appropriate DMTs.
Taking these reviews as a whole, several clear topline themes
emerge, especially around the variety in model structure, the
problems of comparability of results, the limited data available with
a lack of head-to-head RCTs, and the repeated use of a natural
history data set from many decades ago. One speciﬁc complication
that was not extensively considered in these reviews is that in the
European Union some DMTs have different licensed indications and
are used in speciﬁc patient subpopulations; the available RCT data,
however, do not always reﬂect these licensed indications. Since
2013, the launch and economic appraisal of teriﬂunomide, alemtu-
zumab, and dimethyl fumarate has resulted in further proliferation
of models and data sources. The availability of manufacturers’
submissions to NICE provides a rich set of contemporaneous,
detailed, model reports in English, all taking a UK perspective.However, none of the reviews discussed above included NICE
submissions within their remit or identiﬁed any other published
reports of the cost-effectiveness of teriﬂunomide, alemtuzumab, or
dimethyl fumarate. Therefore, there is a need to consider how
models have further developed in the light of these signiﬁcant
new therapeutic options.
Exploration of how the techniques used in modeling RRMS in
the United Kingdom have evolved over time, and critically evalu-
ating these techniques with a focus on methodology, is important
to inform the methodological development of future models. This
will allow these future models to address issues and meet the
challenges facing decision makers appraising DMTs. By restricting
the perspective to one health system, problems of comparability
are reduced and it becomes clearer which methodological points
need to be addressed by the model builder and considered by the
decision maker for any new DMT. Furthermore, given the globally
inﬂuential nature of NICE and the impact of its decisions as one of
the leading health technology appraisal bodies, a review focused
on UK models will draw out modeling insights of global relevance.
Therefore, this review seeks to systematically identify and crit-
ically evaluate the model structures and assumptions used to date
in health economic models of DMTs for RRMS from a UK
perspective. The review also aims to propose practical recommen-
dations for future modeling that address the underlying draw-
backs of models to date, with the recommendations being of
particular interest to both model developers and decision makers.Methods
A systematic review was conducted following the Cochrane
Handbook for Systematic Reviews of Interventions for methods
and the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines for reporting, where appro-
priate [11,12]. The protocol for the systematic review was devel-
oped by the authors and is described fully in this article. The
inclusion/exclusion criteria are listed in Table 1, along with the
rationale for how each relates to the objectives stated above.
Information Sources and Search Strategy
Literature searches were carried out using both MeSH/Emtree and
free text terms for MS, terms relating to treatment, terms relating to
economic models, and terms relating to the United Kingdom.
MEDLINE, MEDLINE In-Process, and Embase databases were
searched on March 3, 2014, via OVID. The Cochrane Library plat-
form was used to search the following databases: Cochrane Data-
base of Systematic Reviews, NHS Economic Evaluation Database,
and Health Technology Assessment database. Full details of all
search terms and time periods used for each database are provided
in Supplemental Material found at http://dx.doi.org/10.1016/j.jval.
2015.05.006. The NICE Web site was also searched to identify
economic models used in manufacturers’ submissions of MS treat-
ments. In addition, reference lists of relevant systematic reviews
were checked to identify any further publications of interest.
Initially, a single reviewer screened the title and abstract of
each result against predeﬁned eligibility criteria. This was fol-
lowed by the same reviewer assessing potentially relevant full
texts against inclusion and exclusion criteria; decisions on full
texts were then checked by a second reviewer. A full list of
excluded full-text articles is given in Supplemental Material
found at http://dx.doi.org/10.1016/j.jval.2015.05.006.
Changes Made during the NICE Appraisal Process
An inherent part of the NICE appraisal process is that manufacturers’
models are critiqued and changes are often requested. For the
included NICE submissions, the changes made during the process
Table 1 – The inclusion/exclusion criteria applied.
Inclusion criteria Rationale
 The participants had a diagnosis of RRMS.
 The intervention was any DMT authorized for use in the United Kingdom to
treat RRMS.
 An analysis from a UK perspective was presented.
 A comparison was made with any other treatment or no treatment; the
outcomes included both costs and clinical outcomes.
 The study design was any form of economic evaluation (cost-consequence,
cost-minimization, cost-effectiveness, cost-utility, or cost-beneﬁt analysis).
 No DMTs are licensed for other forms of MS.
 To reﬂect all current DMT options.
 To maximize comparability.
 To ensure models are relevant to the decision maker and
those building models to inﬂuence decision makers.
 To capture all model types relevant to decision makers.
Exclusion criteria Rationale
 Publications that were not full original reports
 Publications that were not in the English language
 Full reports required for sufﬁcient detail
 Unlikely that UK models would be published in other
languages
DMT, disease-modifying therapy; MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.
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tions are notedwhere relevant in the Results and Discussion sections.
Data Extraction, Quality Assessment, and the Development of
Recommendations for Future Models
For each included study, one reviewer extracted prespeciﬁed data
on the decision problem, model structure, and data sources; this
extraction was checked by a second reviewer. Data were tabu-
lated, and model characteristics and data sources of individual
studies were compared. First, to provide an external anchor for
the assessment of the models, each included study was assessed
by one reviewer against the Drummond criteria [13] (which are
used by NICE in its submission template) and this rating was
checked by a second reviewer. The consideration of the risk of
bias to model results was not considered relevant to this system-
atic review of economic modeling methodology.
Second, in seeking to identify the most important future
considerations for model developers and decision makers, com-
parisons were made between the included models over time,
with special focus on areas in which convergence was not
observed. Furthermore, model capabilities and limitations were
considered with respect to the increasing complexity of treat-
ment options for DMT usage, and areas in which converged
model assumptions have ceased to be appropriate were identi-
ﬁed. From this, recommendations were developed as to how best
to capture this complexity efﬁciently in future models.Results
In line with previous reviews in this area [7,9], the most relevant
considerations for model developers and decision makers did not
emerge directly from the formal assessment of models against
published assessment criteria but rather from examining the evolu-
tion of models over time and considering how the growing complex-
ity of DMT options has affected the continued appropriateness of the
model structures used. The results of the systematic review process
are ﬁrst presented below, followed by the formal quality assessment
of the included studies against the Drummond criteria [13]; this is
then followed by our substantive critical review of the main model-
ing decisions arising from the included models and our proposals on
how these are best addressed inmodeling the current range of DMTs.
Systematic Review Results
The database search process returned 397 results, of which 20
were found to be duplicates. Nine records were identiﬁed throughhand-searching; these included ﬁve manufacturer submissions to
NICE, one commissioned academic report to NICE, and its
addendum, all found by searching the NICE Web site, and two
articles identiﬁed by searching review articles’ bibliographies.
Figure 1 shows as a ﬂow diagram the articles identiﬁed, screened,
retrieved, excluded, and included.
Eleven articles from peer-reviewed journals met the inclusion
criteria [14–24]. The one commissioned academic report to NICE
[25], its addendum [26], and all ﬁve submissions to NICE [27–31]
were also identiﬁed as relevant. Three articles by Parkin et al. [14],
McNamee and Parkin [15], and Parkin et al. [16] described the
same underlying model and because the article published in 2000
[16] provided a less detailed summary, the primary reports used
for data extraction were the original publication from 1998 [14]
and the update incorporating new data published in 1999 [15].
Two articles by Bose et al. [19,20] were found to describe the same
model, and data were initially extracted from the 2001 article [19]
and then checked against the 2002 article [20]. An article by Gani
et al. [24] was found to be based on a manufacturer’s submission
to NICE [27], and once again the more detailed version (the NICE
submission) was used as the primary report for data extraction.
The article by Chilcott et al. [23] was found to be based on the
original School of Health and Related Research (ScHARR) report
commissioned by NICE [25] and its addendum [26], which were
available in full on the NICE Web site and therefore these were
also considered together; the term “the ScHARR model” is used
for these reports hereafter. Therefore, 18 reports on 12 models
were identiﬁed for inclusion and data extraction. All models were
based on the Kurtzke Expanded Disability Status Scale (EDSS) [32],
an ordinal scale describing the severity of disability in patients
with MS. The full data extracted are presented in Tables 2 and 3.
Quality Assessment of Included Reports
The quality assessment against the Drummond criteria [13] rated
results for all models in the “Study Design” section as good but
revealed deﬁciencies in some of the early models in the “Data
Collection” and “Analysis and Interpretation” sections. Two
reports did not clearly describe the model used or the currency
and inﬂation adjustments made [17,18]. Most reports up to 2003
did not report quantities separately to unit costs [17–23,25,26].
Likewise, none of the models before the ScHARR model reported
probabilistic sensitivity analyses [14–22].
Technical Comparison of Models
The model summaries provided in Tables 2 and 3 show a clear
pattern over time, with the ScHARR model commissioned by
Records identified through database 
searching
(n = 397) (The Cochrane Library 
109, Embase 253, Medline 35)
Additional records identified through other 
sources
(n = 9) (5 manufacturer NICE submissions, 1 
commissioned academic report to NICE, 1 
addendum to that report, 2 additional papers 
identified from previous reviews)
Records after duplicates removed
(n = 386)
Records screened
(n = 386)
Records excluded (48 not 
MS patients, 77 not UK,
235 not economic model)
(n = 360)
Full-text articles assessed 
for eligibility
(n = 26)
Full-text articles excluded
(1 editorial, 1 abstract 
only, 2 not an economic 
model, 3 not UK and 1 in 
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Fig. 1 – Flow diagram of the identiﬁcation, screening, and inclusion process.
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diversity in modeling technique, model structure, input data, and
assumptions across the six models developed before the ScHARR
model [14–22]. In contrast, models developed after the ScHARR
model converge with respect to the technique and basic struc-
ture. In line with other recent reviews [7,9], one feature common
to all included models was the use of EDSS to model disability
progression, in spite of criticism of this instrument for its
inability to capture relevant clinical milestones [34]. As one
would expect in a review of models taking a UK perspective,
the impact of changes in guidance issued by NICE over time is
also apparent, both in terms of the recommended discount rates
for costs and utilities and also in terms of the balance between
the risks of extrapolation of limited clinical effectiveness data
versus the desire for a lifetime horizon. Time horizons varied,
with 5, 8, 10, 20 years, and lifetime (represented as 50 years in two
models) all used; more recent models have used longer time
horizons. Short-term studies would have a tendency to under-
estimate the cost-effectiveness of DMTs because the main
advantage of using DMTs is to postpone the development of
severe MS, which occurs after a longer time period.
Of the models published before the ScHARR model in 2003
[23], two appeared to be decision tree models (though were not
explicit in stating their model type) [14–16,18], one described itself
as semi-Markov [21], one simulated individual patients [19,20],
whereas two used forms of regression analysis [17,22]. The
decision tree and Markov-type models [14–16,18,21] used various
cohort structures based on different subsets of EDSS scores. The
regression models attempted to consider the area under the EDSS
score–time curve, in spite of the EDSS score being a series of
ordered categories rather than a cardinal number amenable to
such analysis [17,22]. Only one of the early models attempted toincorporate progression from RRMS to SPMS into its structure in
any form [21]. This model applied inputs from the SPMS pop-
ulation to all patients with an EDSS score of 4.5 or above [21],
which is not consistent with disease progression in clinical
practice [35]. This same model was also the only early example
to incorporate death and treatment withdrawal [21]. None of the
early models reported incorporating the disutility or costs of
adverse events (AEs), subgroup analyses, or probabilistic sensi-
tivity analysis. All early studies provided results from an NHS and
PSS perspective, though it was not the primary perspective for all
the studies—MS has considerable effects on productivity for both
patients and carers; therefore, some models provided results
from a societal perspective [17,18,21]. NICE, however, speciﬁes
an NHS and PSS perspective as the basis for decision making, and
UK models tend therefore to follow this approach; greater
variation in perspective would be expected had other countries
been included in this review. Costs were all discounted by the
then-standard 6%, but utilities were not consistently discounted
by the then-standard 1.5%.
As discussed in the Introduction, the controversy surrounding
the ﬁrst NICE appraisal of beta interferons and glatiramer acetate
led to the commissioning of a new economic model by NICE. The
commissioned model was produced by a consortium led by
ScHARR and is available on the NICE website [25] along with a
short addendum addressing new utility data that became avail-
able after the main report had been submitted but before the
appraisal process was completed [26]. The effect of this process
on those modeling DMTs in MS from a UK perspective is apparent
from the results presented in Tables 2 and 3, and after the
ScHARR model all models describe themselves explicitly as being
based on the ScHARR model. This new model deﬁned a
Markov structure based on the full set of EDSS scores (including
Table 2 – Summary of the included models—authors, funders, and basic model structure.
Study Author and funding Model type Drugs compared Time horizon Cycle length Perspective
Parkin et al. [14],
McNamee and
Parkin [15], and
Parkin et al. [16]
NHS Health Technology
Assessment
programme
Decision tree  IFN-β-1b (Betaferon)
 s.c. IFN-β-1a 44/22 mg
(Rebif 44/22 mg) (1999
article only)
 Best supportive care
5 and 10 y NA NHS & PSS; 6% discount
rate
Kendrick and
Johnson [17]
Biogen; Source of
funding was not
reported within the
article, but is
identiﬁed in NICE
TA32
Regression analysis  i.m. IFN-β-1a 30 mg
(Avonex)
 Best supportive care
20 y NA UK societal and NHS
perspectives both
reported; 6% discount
rate
Phillips et al. [18] Schering—author
afﬁliation; Source of
funding was not
explicitly reported
within the article
Decision tree  IFN-β-1b 250 mg
(Betaferon)
 Best supportive care
10 and 20 y NA NHS and UK societal
perspectives both
presented; discount rate
6% for costs only
Bose et al. [19,20] Aventis and Teva—
author afﬁliations;
Source of funding was
not explicitly reported
within the article
Individual patient
simulation
 Glatiramer acetate
(Copaxone)
 Best supportive care
8 y Not reported NHS; no discounting in the
base case but 6% for both
and 6% costs/1.5% for life
beneﬁts were both also
reported
Nuijten and Hutton
[21]
MEDTAP International
(a health economics
consultancy)
Semi-Markov
process
 IFN-β-1b 250 mg
(Betaferon)
 Best supportive care
Lifetime 3 y NHS and UK societal
perspectives both
presented; 6% discount
rate
Lepen et al. [22] Funded by Serono Time series
regression model
 IFN-β-1a 44/22 mg (Rebif
44/22 mg)
 Best supportive care
10 and 20 y NA 6% discount for cost, no
discount for effectiveness
mentioned; therefore,
none assumed
ScHARR report to
NICE [25], ScHARR
addendum [26],
and Chilcott et al.
[23]
ScHARR funded by NICE Markov  Glatiramer acetate
(Copaxone)
 IFN-β-1a (Avonex)
 IFN-β-1b (Betaferon)
 IFN-β-1a (Rebif 22 and
44 mg)
 Best supportive care
20 y 1 y NHS; costs discounted at
6%, life beneﬁts at 1.5%,
but results at 6% discount
for both are also
presented
Natalizumab
manufacturer’s
NICE STA
submission [27]
and Gani et al. [24]
Biogen, model
developed by Heron
Evidence
Development on their
behalf
Markov
 Natalizumab (Tysabri)
 Glatiramer acetate
(Copaxone)
 Blended comparator:
interferons (Avonex,
Betaferon, Rebif 22 and
44 mg)
 Best supportive care
20 y (NICE
submission)
30 y (Gani et al.
article)
1 y UK societal, UK
governmental, and NHS
& PSS perspectives all
reported; 3.5% discount
rate
continued on next page
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Table 2 – continued
Study Author and funding Model type Drugs compared Time horizon Cycle length Perspective
Fingolimod
manufacturer’s
NICE STA
submission [28]
Novartis Markov Initial submission: 50 y 1 y NHS & PSS; 3.5% discount
rate Fingolimod (Gilenya)
 i.m. IFN-β-1a 30 mg
(Avonex)
Added during appraisal:
 s.c. IFN-β-1b 250 mg
(Betaferon/ Extavia)
 s.c. IFN-β-1a 44/22 mg
(Rebif 44/22 mg)
 Blended comparator:
best supportive care
and interferons
(Avonex, Betaferon,
Extavia, Rebif 22 and
44 mg)
Teriﬂunomide
manufacturer’s
NICE STA
submission [29]
Genzyme Markov  Teriﬂunomide
(Aubagio)
 Blended comparator:
interferons and
glatiramer acetate
 Glatiramer acetate
(Copaxone)
 i.m. IFN-β-1a 30 mg
(Avonex)
 s.c. IFN-β-1b 250 mg
(Betaferon/ Extavia)
 s.c. IFN-β-1a 44/22 mg
(Rebif 44/22 mg)
 Fingolimod (Gilenya)
(HA subgroup only)
 Natalizumab (Tysabri)
(RES subgroup only)
50 y 1 y NHS & PSS; 3.5% discount
rate
Alemtuzumab
manufacturer’s
NICE STA
submission [30]
Genzyme Markov  Alemtuzumab
(Lemtrada)
 Fingolimod (Gilenya)
 Natalizumab (Tysabri)
 Glatiramer acetate
(Copaxone)
 i.m. IFN-β-1a 30 mg
(Avonex)
 s.c. IFN-β-1b 250 mg
(Betaferon/ Extavia)
 s.c. IFN-β-1a 44/22 mg
(Rebif 44/22 mg)
50 y 1 y NHS & PSS; 3.5% discount
rate
continued on next page
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 2 5 – 9 3 8 931the half-number scores as well as the whole-number scores)
incorporating RRMS EDSS states 0–10, SPMS EDSS states 2–10, and
a general death state. Mortality was modeled either as disease
progression to EDSS state 10 (MS death), or as a result of other
causes at any model stage (general death). Patients could tran-
sition from RRMS to SPMS at any point, and adverse effects and
withdrawal from treatment were explicitly considered. Extrapo-
lation of the short-term clinical efﬁcacy data available at the time
was balanced with the long-term nature of the disease through
the choice of a 20-year time horizon. Comprehensive scenario
analyses and probabilistic sensitivity analyses were also
reported, addressing a criticism of many of the previously sub-
mitted models that had presented limited uncertainty analyses.
Subsequent models have clearly converged to a standardized
structure based on that used in the ScHARR model, but with two
modiﬁcations. First, the number of states has been reduced from
the full EDSS set used in the ScHARR model down to a set based
on whole-number states, with each half-number state grouped
with the one above. The exception to this is the EDSS 9.5 state,
which is grouped in with EDSS state 9 (and 8.5). Second, the
separate MS death (EDSS state 10 in each of RRMS and SPMS) and
general death states have been combined into a single absorbing
state. In all the models developed after the ScHARR model, costs
and utilities were both discounted by the current UK standard of
3.5%. In spite of the adoption of this standardized structure,
variation has been apparent in the model assumptions, as will be
discussed below, and also with respect to some aspects of the
data in which there are problems with lack of consensus and
openness of data, with consequences for replicability.
Comparators, the Use of a Blended Comparator, and
Sequencing
The ScHARR model [23,25,26] sought to compare the ﬁrst DMTs to
be made available, that is, the various beta interferons and
glatiramer acetate, with the then-standard best supportive care.
Best supportive care remained a comparator at the time of the
natalizumab and ﬁngolimod NICE appraisals [24,27], alongside
the ﬁrst DMTs, but as can be seen in Table 2, it was removed from
the scope for subsequent NICE appraisals [28–31]. The ﬁngolimod
submission did not consider best supportive care alone, only as
part of a blended comparator. This reﬂects the evolution of the
treatment algorithm for RRMS in the United Kingdom over recent
years, with few patients now receiving best supportive care
alone. In line with the ﬁndings of previous reviews, there is a
lack of head-to-head studies in RRMS and models therefore were
informed by indirect comparisons and network meta-analyses.
Several models designed for NICE included a blended com-
parator that was based on a meta-analysis of the efﬁcacy of
various different therapies and assigned a single weighted cost
[24,27,29]; this was also added in response to appraisal committee
requests during the appraisal process for ﬁngolimod [36]. The
agents included in the blended comparator have changed over
time (see Table 2). Using a blended comparator can appear
advantageous because it simpliﬁes comparisons when there are
many similar agents available. A comparator that would be
considered cost-effective in a pairwise comparison against a
new intervention, however, could be concealed within a non–
cost-effective blended comparator when combined with cost-
inefﬁcient drugs. NICE now does not support the use of a blended
comparator and did not take into account the blended compara-
tor presented in the teriﬂunomide submission [37].
As the number of DMTs available has increased, the need to
consider sequences of treatment with sequential DMTs has
become important; this evolution can be seen in Table 3. From
the ScHARR model onwards, a number of models [23–28,30,31]
have analyzed two lines of treatment, in which a patient can be
Table 3 – Summary of data extracted from included articles—details of model structure and assumptions.
Study Description and
number of
health states
Whether
transition to
death is treated
separately to
EDSS
transitions
No. of lines of
treatment
Any changes in
withdrawal
with time
Any changes in
efﬁcacy with
time
Criteria for
inclusion of
adverse
events
Whether
improvement in
patients’
conditions was
allowed
Subgroups
investigated
Parkin et al. [14],
McNamee and Parkin
[15], and Parkin et al.
[16]
5 states (whole-
number RRMS
EDSS states 3–7)
in IFN-β-1b;
unclear but
more for IFN-β-
1a
Death not
included
1 NR No NR No No
Kendrick and Johnson
[17]
Simple regression
model based on
the EDSS score,
no discrete
health states
NR 1 NR No NR No No
Phillips et al. [18] Uncertain, at least
Parkin’s 5 states
(whole-number
RRMS EDSS
states 3–7);
probably higher
states as well
NR, not included
in the analysis
1, because BSC
after Betaferon
is not analyzed
NR No NR No No
Bose et al. [19,20] No Markov states
because it is not
a Markov model
but patient can
be in 1 of the 10
EDSS states for
RRMS, no SPMS
analyzed
NR, death means
exclusion from
the sample,
which is already
incorporated in
the model
1, because BSC
after GA is not
analyzed
Purely driven by
individual
patient data, so
probably yes but
not speciﬁed
Purely driven by
individual
patient data, so
probably yes but
not speciﬁed
NR Probably yes
because it is an
IPD-driven
model and they
mention this
possibility in
the real setting,
but not stated
explicitly
No
Nuijten and Hutton [21] 9 Markov states
(whole-number
intervals RRMS
EDSS states 2.5–
3.5; SPMS EDSS
states 4.5–9.5;
EDSS state 10 ¼
death)
Yes 1 Yes, applied only
in the ﬁrst cycle
No SAE excluded
from the
analysis
No No
Lepen et al. [22] NR, not a Markov
model, but
there are 10
EDSS states of
RRMS
NR, death means
exclusion from
the sample,
which is already
incorporated in
the model
1, because BSC
after Rebif is not
analyzed
Purely driven by
individual
patient data, so
probably yes but
not speciﬁed
Purely driven by
individual
patient data, so
probably yes but
not speciﬁed
NR Probably yes
because it is an
IPD-driven
model and they
mention this
possibility in
the real setting,
but not stated
explicitly
No
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ScHARR report to NICE
[25], ScHARR
addendum [26], and
Chilcott et al. [23]
38 Markov states
(full RRMS EDSS
states 0–10;
SPMS EDSS
states 2–10;
general death)*
Both transitions to
EDSS state 10
(2) and all-
cause death
2 Discontinuation
10% in ﬁrst and
second years;
3% thereafter
No A general
disutility for
AEs based on
Prosser [33]
and CIC data
is applied. No
speciﬁc AEs
modeled
No No
Natalizumab
manufacturer’s NICE
STA submission [27]
and Gani et al. [24]
19 Markov states
(whole-number
RRMS EDSS
states 0–9; SPMS
EDSS states 2–9;
EDSS state 10 ¼
death)*
Yes 2, no evidence for
more is given
Yes—withdrawal
rates applied for
the ﬁrst 10 y
only; rates
applied to GA
differ between
NICE
submission and
Gani et al.’s
article
No A general
disutility
based on the
ScHARR
model is
applied and
in addition,
for
natalizumab
only, speciﬁc
AEs are
included.
The rationale
for the choice
of AEs is not
speciﬁed
explicitly
Yes SOT and RES
Fingolimod
manufacturer’s NICE
STA submission 2011
[28]
19 Markov states
(whole-number
RRMS EDSS
states 0–9; EDSS
2–9; SPMS EDSS
state 10 ¼
death)*
Yes 2 No Initial submission:
No
General
disutility
model as per
the ScHARR
model for
IFNs and GA.
No general
disutility for
ﬁngolimod
but three
speciﬁc SAEs
modeled.
The rationale
for the choice
of AEs is not
speciﬁed
explicitly
No No
Added during
appraisal: 50%
at 5 y
Teriﬂunomide
manufacturer’s NICE
STA submission [29]
19 Markov states
(whole-number
RRMS EDSS
states 0–9; SPMS
EDSS states 2–9;
EDSS state 10 ¼
death)*
Yes 4 Yes, to 50% of the
initial value
after 2 y
Initial submission: AEs that had
Z4%
probability of
occurrence,
compared
with placebo
Initial submission:
No
HA RRMS and
RESBase case: No
Scenario analyses:
reduced by 25%
or 50% from
year 6 onwards
Added during
appraisal: Yes
Added during
appraisal:
reduced by 25%
after 2 y and
50% after 5 y
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Table 3 – continued
Study Description and
number of
health states
Whether
transition to
death is treated
separately to
EDSS
transitions
No. of lines of
treatment
Any changes in
withdrawal
with time
Any changes in
efﬁcacy with
time
Criteria for
inclusion of
adverse
events
Whether
improvement in
patients’
conditions was
allowed
Subgroups
investigated
Alemtuzumab
manufacturer’s NICE
STA submission [30]
19 Markov states
(whole-number
RRMS EDSS
states 0–9; SPMS
EDSS states 2–9;
EDSS state 10 ¼
death)*
Yes—probability
of death higher
with increasing
EDSS score
2 No withdrawal for
alemtuzumab.
For other DMTs,
after 2 y it is
assumed that
the probability
of withdrawal
will be 50% of
the initial one
Initial submission:
Base case: No
A difference of
Z4% in the
probability of
occurrence,
compared
with placebo.
Where
comparisons
with placebo
data were
not available,
adverse
events with
an incidence
of >5% in the
treatment
arm were
included;
Initial submission:
No
RES and HA
RRMS
Scenario analyses:
reduced by 25%
or 50% from
year 6 onwards
Added during
appraisal:
assume efﬁcacy
waning begins
at 3 or 5 y
Added during
appraisal: Yes
OR
Included within
section 4.4 of
SmPC
detailing
special
warnings
and
precautions
for use
DMF manufacturer’s
NICE STA submission
[31]
19 Markov states
(whole-number
RRMS EDSS
states 0–9; SPMS
EDSS states 2–9;
EDSS state 10 ¼
death)*
Yes 2 No The treatment
effect wanes to
75% after 2 y
and to 50% after
5 y
Most common
AEs on DMF
label (Z5%
incidence in
any
treatment
group in
trials),
common
DMF AEs on
label that
have been
extracted in
the
systematic
review, or
any AE
occurring at
Yes No
continued on next page
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 2 5 – 9 3 8 935moved from the initially assigned active treatment to best
supportive care. With some patients experiencing highly active
disease and requiring second-line treatments, however, modeling
a single active treatment line no longer accurately represents
clinical practice. Only models incorporating three or more lines of
treatment [29] are able to accurately reﬂect the current treatment
pathway. Sequencing is particularly important in this disease
area given the differences in licensed indications between com-
parators and the effect that previous treatments can have on
eligibility for future treatments or the risk of AEs even after
switching treatment. Furthermore, given that the potential com-
parators and sequences available vary depending on the disease
severity experienced by the patient, it is important to be able to
take this into account. Future models need to be able to allow for
such effects methodologically, although direct head-to-head
evidence is likely to be limited for many treatment sequences.
To incorporate each additional line of treatment into a Markov
model requires the creation of all model states and transition
matrices separately for each treatment line. This adds a large
amount of computational intensity to the deterministic model,
with each additional treatment line effectively adding the equiv-
alent of a whole single-treatment-line model. The relative effect
on computational intensity for probabilistic modeling is equiv-
alent, but the absolute increase is greater by several orders of
magnitude. This inherent limitation of Markov models is not
present in some other well-established health economic model-
ing methods such as discrete event simulation (DES) models,
which track each simulated patient individually, yet in a compu-
tationally efﬁcient manner. Such models are capable of making
use of all available data on the effect of both baseline covariates
and the consequences of any modeled events, including patient
eligibility for, and the outcome of, speciﬁc treatment sequences.
Constant or Waning Efﬁcacy and Discontinuation Rate Over
Time
Because clinical trials do not usually cover the whole of the time
horizon relevant to the decision maker, it is necessary to make
assumptions about the efﬁcacy and withdrawal rate of the treat-
ments in the extrapolated period. The ScHARR model [23,25,26]
and the ScHARR-derived models in the natalizumab, ﬁngolimod,
teriﬂunomide, and alemtuzumab NICE submissions [24,27–30]
assumed constant efﬁcacy of DMTs in the base case, whereas
the dimethyl fumarate manufacturer’s NICE submission [31]
assumed that efﬁcacy would fall to 75% of the initial value after
2 years of treatment and to 50% after 5 years. The teriﬂunomide
and alemtuzumab submissions included waning as a scenario
analysis. Waning assumptions were added to the base case in
response to appraisal committee requests during the appraisal
process for ﬁngolimod, teriﬂunomide, and alemtuzumab. All
waning assumptions were arbitrary and were applied equally to
all comparators even though the comparators have differing
propensities to cause neutralizing antibodies [38] and long-term
observational data have been published for some comparators
[39–42]. Similar variation in assumptions was found in the
probabilities of treatment discontinuation: the ScHARR model
[23,25,26] and the natalizumab, teriﬂunomide, and alemtuzumab
manufacturers’ NICE submissions [24,27,29,30] all made differing
assumptions of changes in discontinuation rates over time,
whereas the ﬁngolimod and dimethyl fumarate manufacturers’
NICE submissions [28,31] assumed a constant probability of
discontinuation. This disparity in assumptions makes it difﬁcult
to compare results from different models, and furthermore the
implications of these assumptions are not necessarily straight-
forward. For example, applying a percentage decrease in efﬁcacy
to all comparators could actually favor less effective therapies
when incremental differences are compared.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 2 5 – 9 3 8936Modeling assumptions related to changing efﬁcacy or discon-
tinuation rate over time imply knowledge of the number of years
a patient has been receiving a given treatment. For ﬁrst-line
treatment, this is simply the number of cycles elapsed; however,
as patients enter subsequent lines of treatments at different
times, it becomes necessary to add tunnel states to create
“memory” within the Markov model framework. Such tunnel
states multiply the model size for each additional year of
memory required, introducing considerable complexity and com-
putational intensity. As noted above with respect to treatment
sequencing, use of DES models would remove such difﬁculties by
allowing the efﬁcient incorporation of changing efﬁcacy and
discontinuation rates into subsequent treatment lines.
Improvement in the EDSS Score
Patients with MS experience, on average, a deterioration in their
EDSS score over time, leading to death. It is important to note,
however, that some patients experience spontaneous improve-
ments in condition [43]. The ScHARR model [23,25,26] assumed
that patients cannot be transferred to a lower EDSS score, that is,
their condition cannot improve, and the same assumption was
made in the ﬁngolimod, teriﬂunomide, and alemtuzumab models
[28–30]. Revised natural history data to allow for improvement in
the EDSS score were added to the base case in response to
appraisal committee requests during the appraisal process for
teriﬂunomide and alemtuzumab. Censoring improvement in the
EDSS score could make MS appear more severe than it is; there-
fore, the more recent models allow improvement in disability
levels within the natural history progressions [24,27,31].
An additional complication is that a substantial amount of the
information used in the models submitted to NICE has been
marked as conﬁdential by the submitting manufacturer, making
it impossible to compare and replicate some aspects of these
models; for example, the exact transition probabilities for the
natural history of patients with RRMS in those models that allow
improvement in disability [27,31]. Thus, there are limitations in
the data available to inform other models, even though it is now
considered best practice to include EDSS score improvement
within any model [43]. In line with the ﬁndings of other reviews
[7,9], the models from the ScHARR model onward used, at least in
part, natural history data from the London Ontario cohort [44],
which has been subject to criticism [34]. The recent publication of
a nonconﬁdential natural history data set that allows for
improvement will hopefully address this situation in future, both
with respect to the problems of conﬁdentiality and by providing
an alternative data source for natural history [45].
Use of All-Cause Discontinuation or Discontinuation Due to
AEs
There is no agreement between the models from the ScHARR
model onward with respect to the type of discontinuation
probability applied to the DMTs. The ScHARR model considered
the trial evidence not to be robust and made assumptions about
discontinuation; the natalizumab, teriﬂunomide, alemtuzumab,
and dimethyl fumarate manufacturers’ submissions [24,27,29–31]
used all-cause trial withdrawal, whereas the ﬁngolimod manu-
facturer’s submission [28] used trial withdrawal due to AEs. All-
cause withdrawal takes into account all possible factors affecting
discontinuation, but it also includes withdrawals that are related
to the design of the trial. Furthermore, trial designs differ
between RCTs and hence a degree of unobserved heterogeneity
may be added. It should be noted that discontinuation is an
important parameter in these models and that, nonintuitively, a
higher discontinuation rate can lead to greater cost-effectiveness,
as discussed in the ﬁnal NICE guidance for dimethyl fumarateand teriﬂunomide [37,46]. Because the comparability of with-
drawal rates between trials is of critical importance, the discon-
tinuation rate modeled is therefore a key decision and a
consensus is required as to what is most appropriate.
The Choice of AEs to Include for Each Drug
Another area in which models from the ScHARR model onward
differ signiﬁcantly is the criteria for inclusion of AEs. Some
models [23–28] use AEs from external sources or are not clear
about the reason for the inclusion of AEs, whereas others [29–31]
provide a clear algorithm for the inclusion or exclusion of AEs.
This wide range of approaches results in the same DMT being
modeled with different AE costs and disutilities in different
models, with consequent difﬁculties for comparison of the results
of different models.Conclusions
Overall, this review has found that UK models for RRMS have
converged to a structure of Markov states based on condensed
EDSS score categories, but with remaining variation between
models. This variation is found in the number of lines of treat-
ment allowed, the long-term assumptions around efﬁcacy wan-
ing and withdrawal, the type of withdrawal data used, and the
criteria used for selecting AEs to include, all of which preclude
meaningful comparison of the different model results. Further-
more, data conﬁdentiality has resulted in problems with some
models—even recent ones—failing to allow improvement in the
EDSS score in spite of this now being acknowledged as reﬂective
of the true natural history of the condition.
Strengths and Limitations of This Review
This review included manufacturers’ submissions to NICE and
restricted the inclusion of literature articles to those reporting a
UK perspective. This has allowed the review to provide a
comprehensive and focused analysis of the economic method-
ology informing decision makers in the United Kingdom and
track the evolution of this over time without the analysis being
confounded by the lack of comparability of models between
health systems. Such a focus is particularly timely with the
prospect of the NICE multiple technology appraisal of DMTs for
RRMS expected to initiate towards the end of 2015. In addition,
the transparency of the NICE appraisal process has allowed the
changes made to initial submissions during the appraisal process
to be systematically identiﬁed and permitted relevant changes to
be included in the results and critique presented in this article.
Limitations of the study include the use of a single reviewer to
assess inclusion/exclusion criteria at the abstract review phase;
the fact that NICE submissions are not in themselves peer
reviewed (however, the NICE review process is in effect an open,
rigorous peer review process, the outcomes of which have been
captured systematically in this review); the use of conﬁdential
data in many reports, which limits our ability to review some
aspects of the studies consistently across reports; and the
limitation to studies reporting a UK perspective, which, although
also a strength, omits any ability to track the evolution of models
used to inform decision makers in other health economies.
Implications for Future Modeling
There is now a need to deﬁne and model clinically realistic
treatment pathways, taking into account the increased number
of DMTs, their differing licenses, and the fact that previous
treatments potentially restrict the choice of allowable follow-on
drugs. As previously discussed, however, this will multiply the
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 2 5 – 9 3 8 937complexity of health economic models considerably. Although
Markov cohort models are typically preferred for their relative
simplicity and transparency, the required level of model complex-
ity to capture modern RRMS treatment sequences makes this
modeling technique infeasible. In addition, Markov models are
inherently unable to take into account varying risks by disease
history or account for subgroups such as rapidly evolving severe
or highly active, other than by modeling them as separate
populations. Indeed, if one considers that some recently licensed
DMTs and their speciﬁc AEs have consequences that last beyond
the 1-year cycles used, the Markovian assumption of memoryless
homogenous cohorts ceases to hold, again raising the question of
whether the choice of model technique itself should now be
revisited to better model heterogeneity and treatment complexity.
In considering the best way to address the identiﬁed deﬁcien-
cies and problems in the use of Markov models, it is proposed that
DES models have the potential to become the preferred model type
to capture the required heterogeneity and complexity. The tracking
of individually simulated patients in this type of model allows the
events experienced by patients to modify their future trajectory,
subject to appropriate data being available to inform the inputs.
Markov models cannot capture these effects in a computationally
efﬁcient way. Such a change of model type neatly addresses the
main methodological points identiﬁed in this review, including
greatly facilitating analysis of treatment sequences, tracking the
long-term sequelae of certain treatments, and changes in efﬁcacy
and discontinuation rates with treatment duration. This greater
ﬂexibility seems likely to outweigh the potential downsides of DES
models in terms of programming transparency and reviewer
familiarity with the technique. Although one previous DES model
in RRMS has been published [47], that article considered only a
simple decision problem comparing two beta interferons, based on
extrapolating the results of a single clinical trial over a 4-year
period, and did not incorporate many of the features covered in
this review. A comprehensive new model structure capable of
evaluating the full range of treatment sequences now available
therefore remains to be deﬁned.
In conclusion, although the basic structure used to model
RRMS in the UK setting has seemingly converged over time, there
still remains a great deal of variation between the inputs and
assumptions used in the models. With the increasingly complex
treatment pathway in RRMS, the Markov model structure
designed to assess the ﬁrst DMTs in 2001 is no longer the most
efﬁcient way to model this condition. The time has come for a
paradigm shift in UK RRMS models to reﬂect the clinical advances
of the last decade.
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